Health
Empagliflozin reduces risk of death in patients with heart failure and reduced ejection fraction – News-Medical.Net
Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a reduced ejection fraction.
Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a reduced ejection fraction. That’s the finding of the EMPEROR-Reduced trial presented in a Hot Line session today at ESC Congress 2020.
The EMPEROR-Reduced trial was designed to evaluate the effects of empagliflozin 10 mg once daily (as compared with placebo) in patients with heart failure and a reduced ejection fraction, with or without diabetes, who were already rece…
-
Noosa News17 hours agoWhere, when and why? Everything you need to know about Sunday’s pro-Palestine protest march in Brisbane
-
General23 hours agoNew Spirit of Tasmania ferry arrives in Hobart, but will not be operating for more than a year
-
Noosa News23 hours agoScientists move precious ReefHQ coral ahead of Great Barrier Reef Aquarium build
-
General24 hours agoWA government is ‘spinning’ the results of community survey into Burswood Park racetrack and community hub, locals say